Business
Result of AGM
SkinBioTherapeutics plc announced that all resolutions were passed at its Annual General Meeting, with strong support for the re-appointment of auditors and director remuneration. Key resolutions regarding the allotment of securities for cash, both generally and for acquisitions, also received significant backing, with votes for ranging from 80.84% to 81.34%, indicating shareholder confidence in the company's strategic financial flexibility. Disclaimer*
About this update from Skinbiotherapeutics Plc
[{"type":"text","content":"\n\n\n \nSkinBioTherapeutics plc\n(\"SkinBioTherapeutics\" or \"the Group\")\n \nResult of Annual General Meeting\n \n29 December 2025 - SkinBioTherapeutics plc, (AIM: SBTX, or the \"Company\"), a life science company focused on skin health, held its Annual General Meeting today and all resolutions were passed.\n \n\n\n\n\nResolution\n\n\nVotes For\n\n\nVotes Against\n\n\nVotes Withheld\n\n\n\n\n1. To receive the annual report and accounts\n\n\n88,024,558\n\n\n83.50%\n\n\n17,391,981\n\n\n16.50%\n\n\n722,198\n\n\n\n\n2. To re-appoint Gravita as auditor\n\n\n96,998,314\n\n\n92.15%\n\n\n8,266,920\n\n\n7.85%\n\n\n873,503\n\n\n\n\n3. To authorise Directors to determine Auditors renumeration\n\n\n97,093,358\n\n\n92.13%\n\n\n8,296,876\n\n\n7.87%\n\n\n748,503\n\n\n\n\n4. To authorise the Directors to allot relevant securities\n\n\n85,828,638\n\n\n80.90%\n\n\n20,268,099\n\n\n19.10%\n\n\n42,000\n\n\n\n\n5. To authorise the Directors to allot equity securities for cash without a pre-emptive offer to shareholders\n\n\n85,771,888\n\n\n80.84%\n\n\n20,324,849\n\n\n19.16%\n\n\n 42,000\n\n\n\n\n6. To authorise the Directors to allot equity securities for cash in relation to an acquisition of other capital investment\n\n\n85,782,499\n\n\n81.34%\n\n\n19,682,546\n\n\n18.66%\n\n\n673,692\n\n\n\n\n \nAn electronic copy of the Annual Report and Accounts is available and the results of the AGM will be available on the Company's website in due course at www.skinbiotherapeutics.com/investor-relations.\n \n-Ends-\n \nFor more information please contact:\n \n\n\n\n\nSkinBioTherapeutics plc\nStuart J. Ashman, CEO\nEmily Bertram, Group Finance Director\n\n\n+44 (0) 191 495 7325\n \n\n\n\n\nSinger Capital Markets (Nominated Adviser & Broker)\nPhilip Davies\nAndrew Johnson\nJames Todd\n\n\n+44 (0) 020 7496 3000\n \n\n\n\n\nVigo Consulting (financial press)\nRozi Morris, Melanie Toyne-Sewell\n\n\n+44 (0) 20 7390 0230\[email protected] \n\n\n\n\n \nNotes to Editors\nAbout SkinBioTherapeutics plc\nSkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.\nThe Group's foundation business is targeting the ski...